By winning New York Dx certification, Ariosa gains a valuable marketing tool

Ariosa's Harmony prenatal test--Courtesy of Ariosa Diagnostics

Ariosa Diagnostics won certification from the New York Department of Health's Division of Laboratory Quality Certification to begin selling its Harmony prenatal and reporting test results to New York healthcare providers. That's a big step in what is now the California company's second year aggressively trying to grow its market for the test. Ariosa exists in a reality where diagnostic companies often struggle to make an impact in the marketplace after developing a test, considering that providers don't often shift easily from current standards of care. Additionally, both federal and state reimbursement, as well as a myriad of state regulations, can be hard to obtain and navigate, respectively. New York's laboratory quality standards are quite rigorous, so the milestone ends up being an advertising tool as Ariosa pursues further growth and seeks more customers. Ariosa's other rivals include Sequenom ($SQNM), Natera and Illumina's ($ILMN) Verinata Health. More

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.